Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Patient‐derived organoid (PDO) models are highly valuable and have potentially widespread clinical applications. However, limited information is available regarding organoid models of non‐small cell lung cancer (NSCLC). This study aimed to characterize the consistency between primary tumors in NSCLC and PDOs and to explore the applications of PDOs as preclinical models to understand and predict treatment response during lung cancer.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Fresh tumor samples were harvested for organoid culture. Primary tumor samples and PDOs were analyzed via whole‐exome sequencing. Paired samples were subjected to immunohistochemical analysis. There were 26 antineoplastic drugs tested in the PDOs. Cell viability was assessed using the Cell Titer Glo assay 7–10 days after drug treatment. A heatmap of log‐transformed values of the half‐maximal inhibitory concentrations was generated on the basis of drug responses of PDOs through nonlinear regression (curve fit). A total of 12 patients (stages I–III) were enrolled, and 7 paired surgical tumors and PDOs were analyzed.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>PDOs retained the histological and genetic characteristics of the primary tumors. The concordance between tumors and PDOs in mutations in the top 20 NSCLC‐related genes was >80% in five patients. Sample purity was significantly and positively associated with variant allele frequency (Pearson <i>r </i> = 0.82, <i>P </i> = 0.0005) and chromosome stability. The in vitro response to drug screening with PDOs revealed high correlation with the mutation profiles in the primary tumors. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>PDOs are highly credible models for detecting NSCLC and for prospective prediction of the treatment response for personalized precision medicine.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key points</h3><p>Lung cancer organoid models could save precious time of drug testing on patients, and accurately select anticancer drugs according to the drug sensitivity results, so as to provide a powerful supplement and verification for the gene sequencing.</p></section>

Patient‐Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy

Patient-Derived Organoids (Pdo) As The Potential Model To Predict Treatment Outcome Of Rectal Cancer Patients Underwent Neo-Adjuvant Chemoradiotherapy

A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases

Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer

389PThe establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer

Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer

The Establishment of Patient-Derived Organoid Models and Drug Response of Resectable Non-Small Cell Lung Cancer

Colorectal Cancer Tissue-Originated Spheroids Reveal Tumor Intrinsic Signaling Pathways and Mimic Patient Clinical Chemotherapeutic Response As a Rapid and Valid Model

Genomic characteristics and drug screening among organoids derived fromnon-small celllung cancer patients

"Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction"

Genomic characteristics and drug screening among organoids derived from non‐small cell lung cancer patients

Patient-derived Organoid Model for Predicting the Chemoresponse in Patients With Colorectal Cancer

Integrated Characterization of Hepatobiliary Tumor Organoids Provides a Potential Landscape of Pharmacogenomic Interactions

A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids

Establishment of patient‐derived organoids for guiding personalized therapies in breast cancer patients

Patient-derived organoids of non-small cells lung cancer and their application for drug screening

Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

Paired Organoids from Primary Gastric Cancer and Lymphatic Metastasis Are Useful for Personalized Medicine

Modeling tumor development and metastasis using paired organoids derived from patients with colorectal cancer liver metastases

Patient-derived organoids and mini-PDX for predicting METN375S-mutated lung cancer patient clinical therapeutic response

Patient‐Derived Organoids Can Guide Personalized‐Therapies for Patients with Advanced Breast Cancer